Mutant fully human antibodies that specifically bind to CD22 and their applications
By using phage display technology and mismatch PCR to mutate the CD22 antibody sequence, high-affinity fully human antibodies were screened out, which solved the problem of insufficient affinity of CD22 antibodies in existing technologies and achieved more efficient treatment of tumors and autoimmune inflammation.
Patent Information
- Application Number
- CN202210856495.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-07-20
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2042-07-20
AI Technical Summary
Existing CD22 antibodies are expressed at low abundance on B cells and require high affinity, resulting in a limited number of clinical drugs. Furthermore, existing affinity maturation strategies have limitations, making it difficult to screen for high-affinity antibodies.
The light and heavy chain sequences of CD22 antibody were randomly mutated using phage display technology combined with mismatch PCR. High-affinity fully human antibodies were obtained through affinity screening. The specific steps included blocking, co-incubation, washing and elution, and screening for antibodies that specifically bind to CD22.
A fully humanized antibody with higher affinity for the CD22 antigen was obtained, reducing the risk of immune response and improving the effectiveness of tumor and autoimmune inflammatory treatments.
Smart Images

Figure CN117430703B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of immune engineering technology, specifically relating to a fully human mutant antibody that specifically binds to CD22 or its antigen-binding fragment and its applications. Background Technology
[0002] CD22, also known as Siglec-2, is widely present in normal B cells and B-cell malignancies. CD22 is expressed in a restricted manner on the surface of mature B cells and most B lymphoma cells. It is a cell surface adhesion molecule that regulates B cell activation and helps control the sensitivity of B cells to antigen responses.
[0003] The CD22 molecule inhibits the signaling generated by the BCR complex recognizing antigens. Its regulatory ability on B cell signaling is determined by the proximity of CD22 to the BCR and is also controlled by extracellular interactions. CD22, a co-receptor of the BCR, cross-links with the BCR through antigens or anti-Ig. After cross-linking, CD22 concentrates on lipid rafts, where phosphorylation of membrane-associated protein tyrosine kinase (Lyn) phosphorylates tyrosine residues of CD22. These phosphorylated tyrosine residues become binding sites for the SH2 domains of downstream signaling molecules, which further activate other signaling molecules. For example, the Src homology phosphatase 1 (SHP-1) protein primarily dephosphorylates the BCR, thereby downregulating BCR signaling.
[0004] As a B-cell limiting antigen, CD22 provides an effective target for treating B-cell dysregulation in autoimmune diseases and hematological malignancies. CD22 inhibits the B-cell response to self-antigens by cross-linking with the BCR, preventing the activation of autoreactive B cells and thus suppressing the development of autoimmune diseases. Furthermore, as mentioned earlier, CD22 is expressed only in mature B cells. In most cases, CD22 molecules remain expressed during the transformation of normal B cells into tumor cells. Related data show that approximately 60-80% of B-cell lymphoma and leukemia cells express CD22 molecules.
[0005] In summary, CD22, as one of the inhibitory co-receptors on the surface of B cells, is closely related to the development, differentiation, and function of B cells. Targeting CD22 for tumor immunotherapy has become a hot topic in immunological research. Currently, besides therapeutic antibodies, CAR-T cell therapy is another approach to CD22-targeted immunotherapy. Although the research direction is clear, due to the influence of many uncontrollable factors in antibody development and the low abundance of CD22 expression on B cells, which necessitates high antibody affinity, there are relatively few approved antibody drugs on the market. Therefore, anti-CD22 antibodies still have significant research value as clinical drugs.
[0006] Currently, affinity maturation strategies include (1) mismatch PCR, which introduces random mutations into the gene sequence by changing the PCR reaction conditions to increase the nucleic acid mismatch rate; (2) DNA shuffling technology, which uses deoxyribonuclease I to cut homologous antibody genes into fragments of no more than 50 bp, and then randomly combines them for PCR amplification into complete antibody genes; (3) chain substitution technology, which fixes one light chain or heavy chain of the antibody unchanged, and then mutates another heavy chain or light chain and re-pairs it with the fixed chain to improve antibody affinity; (4) mutant strains, with Escherichia coli MutD5 being the most commonly used Escherichia coli mutant strain. This strain can proofread and replicate mismatch repair defects, producing a high frequency of single base substitutions; (5) CDR recombination, which introduces multiple mutations or designed DNA sequences into multiple CDR regions of the antibody, and then uses antibody library technology to recombine these CDR regions multiple times to achieve affinity maturation.
[0007] Phage display technology is currently the most mature monoclonal antibody drug preparation technology. Proposed by George Smith of the University of Missouri in 1985, its basic principle is to insert exogenous DNA into the genomic DNA of filamentous phages, fuse it with the phage's coat protein, and display it together on the phage surface. As an advanced antibody library construction technology, it can combine multiple techniques to achieve antibody affinity maturation in vitro, overcoming the limitations of sequence diversity in fully human antibody libraries and improving the effectiveness of antibody applications, enabling more targeted screening of high-affinity antibodies.
[0008] The process of affinity maturation for genetically engineered antibodies is essentially an in vitro molecular evolution, involving diverse selection and amplification. Based on our understanding of antibody affinity maturation, the core strategy is to select mutation regions and effectively introduce mutations by mimicking high-frequency somatic mutations. This strategy is mainly categorized into three types: random mutation, substitution, and directed mutation. Studying the affinity maturation of genetically engineered antibodies and preparing high-affinity antibodies can help us achieve the desired biological effects in clinical practice using low doses, reducing dose-induced toxicity, and increasing therapeutic efficacy. This is crucial in the development of antibody drugs. Summary of the Invention
[0009] To screen for affinity-matured antibodies targeting the CD22 antigen, this protocol employs sequence mutagenesis combined with phage display technology for affinity maturation. Specifically, to obtain antibodies with high affinity, this protocol utilizes the affinity maturation method of phage display technology, employing mismatch PCR to modify the sequence (the light chain sequence is as follows: ETTLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAIYYCQQYHS) WPPLTFGGGTKLEIKR; The heavy chain sequence is as follows: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDFQGIAVADLDYWGQGTLVTVSS) is randomly mutated and combined with affinity screening methods to obtain antibodies with high affinity, and finally obtains scFv with higher specificity binding to CD22 antigen.
[0010] The present invention provides an antibody or its antigen-binding fragment capable of specifically binding to CD22, comprising a heavy chain variable region and a light chain variable region; wherein the light chain variable region comprises L-CDR1, L-CDR2 and L-CDR3, and the heavy chain variable region comprises H-CDR1, H-CDR2 and H-CDR3;
[0011] The L-CDR1, L-CDR2 and L-CDR3 are respectively the following sequences: QSVSSNL, GAS, QQYHSWPPLT;
[0012] The H-CDR1, H-CDR2, and H-CDR3 are respectively the following sequences:
[0013] GYSFTSYG,ISAYNGNT,ARDFQGIAVADLDY.
[0014] Furthermore, the amino acid sequence of the light chain variable region is as shown in Sequence NO.1 or a functional variant thereof, and Sequence NO.2 is a mutant sequence of Sequence NO.1; the amino acid sequence of the heavy chain variable region is as shown in Sequence NO.3 or a functional variant thereof, and Sequence NO.3 is a mutant sequence of Sequence NO.4.
[0015] Furthermore, the antibody or its antigen-binding fragment is selected from ScFv, Fab, Fab', bispecific antibodies, and multispecific antibodies.
[0016] Furthermore, the ScFv is arranged in the form of VL-Linker-VH or VH-Linker-VL.
[0017] Furthermore, the amino acid sequence of the Linker is shown in Sequence NO.5.
[0018] In some embodiments, the antibody or its antigen-binding fragment is selected from ScFv, Fab, Fab', bispecific antibodies, and multispecific antibodies, and can be directly or indirectly coupled / bound to a cytotoxic agent to form an immunodrug conjugate or antibody-drug conjugate (ADC). Antibody-drug conjugates (ADCs) are a class of targeted biopharmaceuticals that link cytotoxic drugs to monoclonal antibodies via covalent compound linkers. In some embodiments, the cytotoxic agent can be a microtubule inhibitor and / or a DNA damaging agent, specifically such as α-amanitin (selective RNA polymerase II inhibitor), DM1, PBD, MMAE (monomethylauristatin E), N-acetyl-gamma-calicheamicin, mitomycin C, anthracyclines, methotrexate, camptothecin derivatives, SN-38, and other toxin molecules.
[0019] The antibody in this invention can be a single-chain antibody. A single-chain antibody can be obtained by linking the heavy chain variable region and the light chain variable region of the antibody via a polypeptide linker.
[0020] In some embodiments, the antibody described in this invention may be a multispecific antibody, preferably a bispecific monoclonal antibody (BsAb). The other targeting molecule of the bispecific antibody may be a surface marker of immune cells, specifically a T cell surface marker, which forms a bispecific T cell engager (BiTE) with the antibody described in this invention. In some embodiments, the T cell surface marker molecule is CD3. In some embodiments, the bispecific antibody, in addition to the antibody against CD22 described in this invention, also includes an antibody against immune checkpoints. The surface molecules targeted by the immune checkpoint antibody may be: PD1, PDL1, CTLA4, CD47, TIGHT, TIM3, BTLA, LMTK3, etc. In some embodiments, the bispecific antibody comprises, in addition to the antibody against CD22 described in this invention, an antibody against tumor surface molecules, which include, but are not limited to: CD19, CD20, CD22, CD33, CLL-1 (CLEC12A), CD7, CD5, CD70, CD123, CEACAM5, CEACAM6, CEACAM7, Mesothelin, MUC1, CLDN18.2, CDH17, Trop2, BCMA, NKG2D, PDL1, EGFR, EGFRVIII, PSCA, PSMA, MUC16, CD133, GD2, IL13R2, B7H3, Her2, CD30, SLAMF7, CD38, GPC3, WT1, or TAG-72.
[0021] Furthermore, the antibody or its antigen-binding fragment is selected from ScFv, Fab, Fab', bispecific antibodies, and multispecific antibodies, and can be combined with immune checkpoint inhibitors. These immune checkpoint inhibitors include, but are not limited to, CTLA-4 inhibitors, PD-1 / PD-L1 inhibitors, LAG-3 (Lymphocyte Activation Gene-3) inhibitors, TIM-3 (T cell immunoglobulin-3), TIGIT (T cell immunoglobulin and ITIM domain protein), and BTLA inhibitors. In some embodiments, these inhibitors are small molecule drugs, and in others, they may be antibodies, active peptides, etc. Furthermore, the ScFv, Fab, Fab', bispecific antibodies, and multispecific antibodies described in this invention can be combined with chemical drugs.
[0022] The present invention also provides a nucleic acid molecule comprising any of the antibodies or antigen-binding fragments described above.
[0023] Furthermore, the nucleotide sequence encoding the antibody heavy chain variable region in the nucleic acid molecule is shown in Sequence No. 7 or a functional variant thereof; wherein the nucleotide sequence encoding the antibody light chain variable region is shown in Sequence No. 6 or a functional variant thereof.
[0024] The present invention also provides a recombinant plasmid comprising the above-described nucleic acid molecules.
[0025] Furthermore, the recombinant plasmid also includes an expression vector, which is a lentiviral expression vector, a retroviral expression vector, an adenovirus expression vector, a DNA vector, or an RNA vector.
[0026] Furthermore, the lentiviral vector is selected from the group consisting essentially of: human immunodeficiency virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2), visna-maedi virus (VMV), caprine arthritis-encephalitis virus (CAEV), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV), and simian immunodeficiency virus (SIV).
[0027] Furthermore, the vector contains a left (5') retroviral LTR, a Psi(Ψ) packaging signal, a central polypurine segment / DNA flap (cPPT / FLAP), a retroviral export element, a promoter operatively linked to a multinucleotide encoding the chimeric antigen receptor covered herein, and a right (3') retroviral LTR.
[0028] Furthermore, the chimeric antigen receptor comprises a hepatitis B virus post-transcriptional regulatory element (HPRE) or a prairie dog post-transcriptional regulatory element (WPRE) and an optimized prairie dog post-transcriptional regulatory element (oPRE).
[0029] Furthermore, the promoter of the 5'LTR is replaced by a heterologous promoter.
[0030] Furthermore, the heterologous promoter is a cytomegalovirus (CMV) promoter, a Rous Sarcoma Virus (RSV) promoter, or a simian virus 40 (SV40) promoter.
[0031] Furthermore, the 5'LTR or 3'LTR is a lentiviral LTR.
[0032] Furthermore, the 3'LTR is a self-inactivating (SIN)LTR.
[0033] The present invention also provides a chimeric antigen receptor comprising an antibody or its antigen-binding fragment as described in any one of the above claims as an ScFv, wherein the chimeric antigen receptor includes a hinge region, a transmembrane region, and an intracellular signaling region. The hinge region sequence may be derived from: IgG, CD8, CD7, CD4 or other equivalent functional protein molecules; the transmembrane region may be derived from: type I transmembrane protein, CD8, CD28, CD3ε, CD4, CD16, CD137, CD134, CD278, Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, CD40L, CD134 (OX-40), CD7, CD80 and CD86 or other equivalent functional protein molecules; the intracellular signaling region may be derived from: CD3, CD137, CD28, CD27, OX40, ICOS, GITR, CD2, CD40, PD-1, PD1L, B7-H3, lymphocyte function-associated antigen-1 (LFA-1), ICAM-1, CD7, NKG2C, CD83, CD86 and CD127 or other equivalent functional protein molecules.
[0034] Furthermore, the chimeric antigen receptor comprises one or more components of a natural killer cell receptor (NKR), thus forming an NKR-CAR. The NKR component can be derived from the transmembrane domain, hinge domain, or cytoplasmic domain of any of the following natural killer cell receptors: killer cell immunoglobulin-like receptors (KIRs), such as KIR2DL1, KIR2DL2 / L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, DIR2DS5, KIR3DL1 / S1, KIR3DL2, KIR3DL3, etc. KIR2DP1 and KIR3DP1; native cytotoxic receptors (NCRs), such as NKp30, NKp44, and NKp46; the lymphocyte activation molecule (SLAM) family of immune cell receptor signaling molecules, such as CD48, CD229, 2B4, CD84, NTB-A, CRA, BLAME, and CD2F-10; Fc receptors (FcRs), such as CD16 and CD64; and Ly49 receptors, such as LY49A and LY49C. The NKR-CAR molecules described herein can interact with adaptor molecules or intracellular signaling domains (e.g., DAP12).
[0035] Furthermore, the chimeric antigen receptor can be combined with / in combination with fusion proteins of tumor suppressor molecules, cytokines, T-cell activating molecules, etc. The molecule that reverses tumor suppressor signals can be PD1, and the fusion protein structure can be any structure of PD1 extracellular segment-hinge-transmembrane-intracellular signaling region, or PD1 extracellular segment and membrane region-intracellular signaling region, etc. The diverse forms of fusion proteins and the different structures of fusion proteins do not affect the function of the chimeric antigen receptor of the present invention in recognizing CD22. Therefore, those skilled in the art can easily combine the chimeric antigen receptor of the present invention with any structure of fusion protein / peptide. In addition to the PD1 molecule mentioned above, tumor suppressor molecules can also be CTLA-4, PD-L1, LAG-3, TIM-3, BTLA, CD47, etc.; cytokines can be membrane-bound IL-15, membrane-bound IL12, membrane-bound IL21, etc.; T-cell activating molecules can be CD80, CD86, etc.
[0036] Furthermore, the chimeric antigen receptor comprises secretible cytokines, antibodies, or other polypeptides.
[0037] Furthermore, the chimeric antigen receptor contains identifiable marker molecules, which may be truncated receptors such as truncated EGFR (EGFRt), truncated HER2 (HER2t), truncated CD34 (CD34t), and truncated CD19 (CD19t).
[0038] Furthermore, the chimeric antigen receptor can be combined with an immune checkpoint inhibitor, which includes, but is not limited to: CTLA-4 inhibitors, PD-1 / PD-L1 inhibitors, LAG-3 (Lymphocyte ActivationGene-3) inhibitors, TIM-3 (T cell immunoglobulin-3), TIGIT (T cell immunoglobulin and ITIM domain protein), and BTLA inhibitors. In some embodiments, the inhibitor is a small molecule drug, and in some embodiments, it can be an antibody, an active peptide, etc.
[0039] Furthermore, the chimeric antigen receptor includes ScFv or a functional variant thereof, as shown in Sequence No. 8.
[0040] The term "scFv" refers to a single polypeptide chain containing VL and VH domains linked by a linker (see, for example, Bird et al., Science 242:423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, edited by Roseburg and Moore, Springer-Verlag, New York, pp. 269-315 (1994)). Such scFv molecules may have a general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable prior art linkers consist of repeating GGGGS amino acid sequences or GSTGSGSGKPGSGEGSTKG amino acid sequences or variants thereof. For example, a linker having the amino acid sequence (GGGGS)4 or GSTGSGSGKPGSGEGSTKG can be used, but variants thereof can also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448). Other linkers that can be used in this invention are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56, and Roovers et al. (2001), Cancer Immunol.; the linker does not need to affect the function or properties of the antibody itself, and any existing disclosed linker can be used.
[0041] The present invention also provides an immune engineered cell, wherein the immune engineered cell is obtained by transfecting immune cells with the recombinant plasmid described above, or the immune engineered cell contains the chimeric antigen receptor described above.
[0042] Furthermore, the immune cells are T cells, T cell precursors, macrophages, NKT cells, γδT cells, or NK cells.
[0043] The present invention also provides the use of any of the antibodies or antigen-binding fragments described above, or the nucleic acid molecules described above, or the recombinant plasmids described above, or the chimeric antigen receptors described above, or the immune engineered cells described above in the preparation of antitumor / autoimmune inflammatory drugs.
[0044] Furthermore, the tumor / autoimmune inflammation is B-cell lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, chronic lymphoblastic leukemia, or systemic lupus erythematosus.
[0045] The present invention also provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof described above, or the nucleic acid assay described above, or the recombinant plasmid described above, or the chimeric antigen receptor described above, or the immune engineered cell described above.
[0046] The present invention also provides the use of the antibodies or antigen-binding fragments described above in the preparation of detection reagents / test kits.
[0047] In this invention, a “functional variant” generally refers to an amino acid sequence that has substantially the same function as the chimeric antigen receptor (e.g., may possess the properties of the chimeric antigen receptor) and has at least 85% (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100%) sequence identity with it.
[0048] In this invention, the antibody or its antigen-binding fragment can be linked to a detectable marker. The detectable marker can be any substance that can be detected by fluorescence, spectroscopy, photochemistry, biochemistry, immunology, electrical, optical or chemical means. Such markers are well known in the art, and examples include, but are not limited to, enzymes (e.g., horseradish peroxidase, alkaline phosphatase, β-galactosidase, urease, glucose oxidase, etc.), radionuclides (e.g., 3H, 125I, 35S, 14C, or 32P), fluorescent dyes (e.g., fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC), phycoerythrin (PE), Texas red, rhodamine, quantum dots, or cyanine dye derivatives (e.g., Cy7, Alexa750)), acridine esters, magnetic beads (e.g., [missing information]), calorimetric markers such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads, and biotin for binding avidin (e.g., streptavidin) modified with the above markers.
[0049] The beneficial effects of this invention are as follows:
[0050] (1) This invention utilizes phage display technology and mismatch PCR to perform on-the-fly mutations on sequences (light chain sequence as follows: ETTLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAIYYCQQYHSWPPLTFGGGTKLEIKR; heavy chain sequence as follows: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDFQGIAVADLDYWGQGTLVTVSS) to screen for fully humanized antibodies with higher affinity for human CD22 antigen, which has potential clinical therapeutic advantages.
[0051] (2) The antibody or its antigen-binding fragment provided by the present invention is fully human, has low human immunogenicity, and can specifically recognize human CD22 antigen, which can be better applied to the treatment of tumors or autoimmune inflammations targeting CD22. Attached Figure Description
[0052] Figure 1 Flow cytometry staining of NALM6 (CD22-) cells with target antibody
[0053] Figure 2 Flow cytometry staining of NALM6 (CD22+) cells with target antibody
[0054] Figure 3 To measure the effect of different concentrations of antibody (μg / mL) on NALM6 (CD22+) cells by flow cytometry.
[0055] Figure 4 To fit the flow cytometry affinity of graded dilution antibodies to the target antibody
[0056] Figure 5 To detect the binding kinetics of the target antibody to the CD22 antigen
[0057] Figure 6 SA-01-D06 for flow cytometry staining of NALM6 (CD22-) cells
[0058] Figure 7 SA-01-D06 for flow cytometry staining of NALM6 (CD22+) cells
[0059] Figure 8 Flow cytometry staining of NALM6 (CD22+) cells with different concentrations (μg / mL) of SA-01-D06 antibody
[0060] Figure 9 Flow cytometry affinity fitting for serially diluted SA-01-D06 antibody
[0061] Figure 10 Detection of binding kinetics between SA-01-D06 and CD22 antigen Detailed Implementation
[0062] The embodiments described are provided to better illustrate the present invention, but are not intended to limit the scope of the invention to the embodiments described. Therefore, non-essential improvements and adjustments made to the embodiments by those skilled in the art based on the above description are still within the scope of protection of the present invention.
[0063] The antibodies of the present invention can be complete immunoglobulin molecules or antigen-binding fragments, including but not limited to Fab fragments, Fd fragments, Fv fragments, F(ab')2 fragments, complementarity-determining region (CDR) fragments, single-chain antibodies (scFv), domain antibodies, bivalent single-chain antibodies, single-chain phage antibodies, bispecific double-chain antibodies, triple-chain antibodies, and quadruple-chain antibodies.
[0064] The specific implementation process of antigen screening in this invention is as follows:
[0065] a. Blocking: 3% skim milk powder was dissolved in PBS, filtered through a 0.45μm filter membrane and used as blocking solution. The phage and CD22-protein G coupled magnetic beads were resuspended in an appropriate amount of blocking solution and mixed by rolling at 160 rpm for 1 h at room temperature.
[0066] b. Co-incubation: Place the CD22-proteinG-conjugated magnetic beads in a magnetic rack, discard the supernatant, resuspend the magnetic beads with phage, and co-incubate at room temperature and 160 rpm for 1 hour.
[0067] c. Washing: Place the magnetic bead phage mixture on a magnetic rack, discard the supernatant, and add an appropriate volume of 0.1% Tween-20 PBST washing solution to wash the magnetic beads. The number of washing cycles is determined according to the number of panning rounds. For the first panning round, wash 10 times with PBST and 3 times with PBS; for the second panning round, wash 16 times with PBST and 3 times with PBS; for the third panning round, wash 20 times with PBST and 3 times with PBS.
[0068] d. Elution: Place the washed magnetic beads on a magnetic rack, aspirate the supernatant, add 400 μL of pH 2.2 Gly-HCl, mix well, and incubate at room temperature for 7 min. Then add about 20 μL of pH 9.0 Tris-HCl to adjust the pH to near neutral. Finally, place the mixture on a magnetic rack and transfer the phage supernatant to a new 1.5 mL EP tube to complete one round of panning.
[0069] e. Enrichment: Inoculate the phage into TGI bacterial culture with an OD600 of approximately 0.5 for infection. After standing at 37°C for 30 min, centrifuge at 4000 rpm, retain 200 μL of culture medium to resuspend the precipitate, spread it on a 2YTAG plate, and incubate overnight at 30°C with the plate inverted.
[0070] f. Plate washing: Wash the overnight culture plates off the bacterial plaques from the culture medium to obtain the seed culture for the next round of library packaging. The specific process is the same as that for the preparation of affinity maturation libraries.
[0071] The specific implementation process of chemiluminescence detection in this invention is as follows:
[0072] a. Obtaining phage samples: Centrifuge the overnight cultured phage monoclonal recombinant bacterial solution at 4℃ and 8000rpm for 10min, and take the supernatant as the test sample;
[0073] b. Cell incubation: Dilute K562 and K562-CD22 with PBS to a cell volume of 2.5×106 / mL, aliquot 200uL into a 96-well plate, centrifuge at 400g for 3min and discard the supernatant, add 100uL of phage to each well, and incubate at 4℃ for 30min.
[0074] c. Secondary antibody incubation: Wash twice with PBS, centrifuge at 400g for 3 min and discard the supernatant. Add 100 μL of Anti-M13-HRP secondary antibody diluted 1:15000 to each well and incubate at 4℃ for 30 min.
[0075] d. Color development: Wash twice with PBS, centrifuge at 400g for 3 min and discard the supernatant. Add 25uL of ECL color development solution Solution I to each well to resuspend the cells. After transferring to the detection plate, add 25uL of Solution II to each well.
[0076] e. Detection: Immediately place the test plate in an ELISA reader to detect fluorescence. A detection value higher than 1×10⁻⁶ is acceptable. 8 The phage clones were re-examined in the next round.
[0077] The specific implementation process of ELISA detection in this invention is as follows:
[0078] a. Coating: Dilute CD22 antigen to 1 μg / mL with 50 mM pH 9.6 carbonate coating buffer, add 100 μL / well to a 96-well plate, and incubate overnight at 4°C.
[0079] b. Obtaining phage samples: Centrifuge the overnight cultured phage monoclonal recombinant bacterial solution at 4℃ and 8000rpm for 10min, and take the supernatant as the test sample;
[0080] c. Blocking: After washing the antigen-coated plate three times with PBS on a plate washer, add 200 μL of 5% skim milk blocking solution to each well and block at 37°C for 2 hours;
[0081] d. Antibody incubation: After washing the plate 3 times with PBS, add 100 μL of the recombinant monoclonal bacterial suspension of the phage to be tested to each well and incubate at 37°C for 1 h;
[0082] e. Add secondary antibody: Wash the plate 3 times with PBS using a plate washer, add 100 μL of 1:15000 Anti-M13-HRP secondary antibody to each well, and incubate at 37°C for 1 h;
[0083] f. Color development: Wash the plate 6 times with a plate washer, add 100μL of TMB color development solution to each well, and let it stand at room temperature in the dark for 25 minutes to develop color.
[0084] g. Termination: Add 50 μL of 2M H2SO4 to each well to terminate the reaction;
[0085] h. Detection: Place the test plate in an ELISA reader and measure the OD450 absorbance. If the absorbance is higher than that of the SK-03-B09 phage clone and is stable, it is a positive clone.
[0086] Example 1: Construction of a fully human single-chain antibody library
[0087] PBMCs were separated using Ficoll separation solution. The Ficoll solution was slowly added to normal human blood to maintain a clear separation interface between the Ficoll solution and the blood. A 50 mL centrifuge tube containing the blood and separation solution was centrifuged at approximately 15°C for 20 minutes. After centrifugation, the liquid surface separated into four layers: an upper layer of plasma mixture, a lower layer of erythrocytes and granulocytes, and a middle layer of Ficoll solution. At the boundary between the upper and middle layers, there was a narrow band of white, cloudy layer dominated by PBMCs, which was the PBMC cell layer. The upper plasma mixture was carefully aspirated using a sterile Pasteur pipette, and then the PBMCs were aspirated using a new sterile Pasteur pipette to obtain the separated PBMCs.
[0088] Total RNA was extracted using conventional methods and reverse transcribed into cDNA. Primers were then designed according to the method described in Sblattero, D., Bradbury, A., (1998) A definitive set of oligonucleotide primers for amplifying human Vregions. Immunotechnology 3, 271-278, with VL preceding or following VH, and the middle linked by a flexible linker. PCR was used to obtain the heavy chain variable region gene fragment and the light chain variable region gene fragment of the antibody. The scFv nucleic acid fragment was amplified using conventional overlap PCR (PCR method referred to "Molecular Cloning: A Laboratory Manual" (3rd edition), USA, Joe Sambrook, David Russell, Science Press). The scFv nucleic acid fragment was ligated into the phage vector pComb3XSS, and the product was transformed into TGI strains using an electroporator to obtain a fully human single-chain antibody library.
[0089] Example 2: Construction of the Affinity Maturation Library
[0090] Antibodies with the following sequences were screened from a fully human single-chain antibody library: (Light chain sequences: ETTLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAIYYCQQYHSWPPLTFGGGTKLEIKR; Heavy chain sequences: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWIS) The template was prepared as follows: AYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDFQGIAVADLDYWGQGTLVTVSS (linker: GGSTSGSGKPGSGEGSTKG). Primers were designed at both ends for the screened antibodies. Mismatch PCR was performed using the rTaq system. The system was modified based on the manufacturer's instructions (TaKaRa) by increasing the concentrations of MgCl2 (3.5 mM), dCTP / dTTP (0.8 mM), and MnCl2 (0.5 mM). The first round of amplification required 50 ng of template, and PCR was performed for 30 cycles. The recovered template was used as the template for the second round of amplification. The amount of template and the number of amplification cycles were reduced for the second round of amplification, resulting in a mutant library of the scFv nucleic acid fragment. The scFv nucleic acid fragment was ligated into the phage vector pComb3XSS, and the product was transformed into the TG1 strain using electroporation to obtain an affinity maturation library.
[0091] Example 3: Preparation of a phage display affinity maturation library
[0092] Add the bacterial culture to fresh SOC liquid medium with ampicillin at a concentration of 100 μg / mL, and resuscitate at 37°C and 250 rpm. Incubate until OD600 ≈ 0.5, then add VSCM13 helper phage at a VCSM13:bacteria ratio of 50:1, mix thoroughly, incubate for 30 min, and then continue incubation on a shaker. Centrifuge the culture and discard the supernatant. Resuspend the precipitate in SOB medium containing 50 μg / mL ampicillin and 50 μg / mL kanamycin, and incubate overnight at 30°C and 250 rpm. Centrifuge the bacterial culture at 4°C and 8000 rpm, collect the supernatant, add 1 / 5 volume of 20% PEG 8000 2.5 mmol / L NaCl solution, incubate on ice, then centrifuge at 4°C and 12000 rpm. Resuspend the precipitated phage in PBS, centrifuge at 4°C and 15000 rpm, and collect the supernatant.
[0093] Example 4 Antigen Selection
[0094] CD22 protein with an Fc tag was co-incubated with proteinG magnetic beads to prepare CD22-proteinG-coupled magnetic beads. The coupled magnetic beads were then extracted into a prepared phage affinity maturation library for selection. After several rounds of co-incubation, washing, and elution, specific monoclonal antibodies against the CD22 antigen were enriched.
[0095] Example 5: Screening of positive clones
[0096] After the initial screening, the final batch of monoclonal plaques were selected for chemiluminescence detection and then retested using ELISA. Phage clones binding to the CD22 antigen were obtained and applied to downstream research, resulting in the screening of the following antibodies:
[0097]
[0098] Example 6: Expression and purification of scFv
[0099] 100 ng of pComb3XSS plasmid containing a positive phage clone was mixed with 100 μL of competent Rosetta gami (DE3) bacteria and incubated on ice. The mixture was then heat-shocked at 42°C for 90 s. After the ice bath, the mixture was spread onto LB agar plates containing ampicillin and incubated overnight at 37°C. Single colonies were picked and placed in LB medium. After 8 h of shaking culture, the bacterial culture was transferred to 200 mL of LB medium and cultured. When the OD of the bacterial culture reached 0.5-1.0, IPTG was added and the final concentration was adjusted to 1 mM. Expression was induced at 37°C for h. The bacterial cells were collected by centrifugation at 3600 rpm, and the precipitate was resuspended in PBS. The lysis buffer was sonicated, centrifuged at 12000 rpm at 4°C, the precipitate was discarded, and the supernatant was collected for protein purification.
[0100] The supernatant from bacterial lysis was filtered through a 0.22 μm filter, diluted to an equal volume, and enriched with scFv using a GE Ni Sepharose Excel purification column. After washing with PBS, impurities were removed by washing with imidazole PBS solution, and proteins were eluted. The eluent was collected and concentrated using a 3 kDa ultrafiltration tube. The eluent was loaded onto a GE HiLoad Superdex 16 / 600 200 pg size exclusion column, washed with PBS, and the UV absorption peak was collected. The purification effect of scFv was identified by SDS-PAGE, and then flow cytometry was used for specific detection.
[0101] Example 7: Comparison of Flow Cytometry Staining Capabilities
[0102] NALM6 (CD22-) and NALM6 (CD22+) cells were separately dispensed into Eppendorf tubes, 5 × 10⁶ cells per tube. 5Cells were used as target cells. After centrifugation, the supernatant was discarded. SK-03-B08, SA-01-A18, SA-01-B07, SA-01-B12, and SA-01-D06scFv solutions were diluted to 30 μg / mL, and then down-diluted 2-fold to four gradients: 15 μg / mL, 7.5 μg / mL, 3.75 μg / mL, and 1.875 μg / mL. Target cells were resuspended in PBS as a control sample and incubated at 4°C. Cells were resuspended in PBS, centrifuged, and the supernatant was discarded. The fluorescent secondary antibody for detection was added, cells were resuspended, and incubated at 4°C in the dark. The cells were then resuspended, washed twice, centrifuged, and the supernatant was discarded. The cells were then resuspended in PBS and transferred to detection tubes for analysis. The positive rate and mean fluorescence intensity (MFI) of flow cytometry staining were measured. The selected anti-CD22scFv was compared with the antibody screened from a fully human single-chain antibody library (named: target antibody) (the light chain sequence is as follows:).
[0103] The heavy chain sequence is as follows: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDFQGIAVADLDYWGQGTLVTVSS, linker is GGSTSGSGKPGSGEGSTKG). Flow cytometry staining results were used to assess the flow cytometry staining specificity of affinity-matured scFv. Flow cytometry staining results of the target antibody scFv against NALM6 (CD22-) are as follows. Figure 1 As shown, flow cytometry staining of NALM6(CD22+) cells is as follows: Figure 2 As shown, the flow cytometry staining results of NALM6 (CD22+) cells with different concentrations of scFv (μg / mL) are as follows: Figure 3 As shown, its flow cytometry affinity fitting is as follows: Figure 4 As shown; the staining results of NALM6(CD22-) cells obtained by panning for CD22-specific scFv are as follows. Figure 6 As shown, the flow cytometry staining results for NALM6(CD22+) are as follows: Figure 7 As shown, the flow cytometry staining results of NALM6 (CD22+) with different concentrations of antibody (μg / mL) are as follows. Figure 8 As shown, its flow cytometry affinity fitting is as follows: Figure 9 As shown.
[0104] Table 1 Comparison of affinity between the target antibody and SA-01-D06
[0105] Antibody KD(nM) Target antibody 47.7 SA-01-D06 26
[0106] As shown in Table 1, the KD values of the target antibody and the affinity-matured antibody are compared. Based on the flow cytometry staining results of the serially diluted samples, the KD value was calculated by affinity fitting. The KD value of the target antibody was 47.7 nM, while the KD value of the antibody selected through affinity maturation screening was less than 47.7, proving that its affinity was better than that of the target antibody.
[0107] Example 8: Comparison of kinetic parameters for antigen-antibody binding
[0108] The SA / HIS1K biosensor underwent a series of induction cycles: baseline 1 for 60 seconds in analysis buffer, followed by loading in scFv solution for 120 seconds to immobilize the ligand protein; baseline 2 for 120 seconds in analysis buffer; serially diluted analyte (CD22 monovalent antigen) solution for 120 seconds; and finally, in analysis buffer for 300 seconds. The presence of specific binding was determined by monitoring changes in the response value R. Generally, specific binding is indicated when the maximum response value Rmax after adjusting for reference is greater than 0.05 nm and exhibits concentration dependence and dissociation. The Fortebio Octet K2 instrument's built-in Data Analysis software provides kinetic parameters represented by the binding-dissociation curves, such as the binding constant (Kon), dissociation constant (Kdis), and equilibrium dissociation constant (KD). Kon, measured in units of 1 / Ms, describes the rate of antigen-antibody binding; a higher Kon indicates a faster formation of the complex. Kdis, measured in units of 1 / s, describes the rate of antigen-antibody dissociation; a higher Kdis indicates a faster dissociation of the antigen-antibody complex. KD, the ratio of Kdis to Kon, comprehensively describes the ease of antigen-antibody binding; a smaller KD generally indicates higher antibody affinity. The binding kinetics of the target antibody scFv with the CD22 antigen are as follows: Figure 5 As shown, the binding kinetics of the CD22-specific scFv obtained by panning to the CD22 antigen are as follows: Figure 10 As shown in the figure, the CD22-specific scFv obtained by panning can bind to the CD22 antigen.
Claims
1. An antibody or its antigen-binding fragment capable of specifically binding to CD22, characterized in that, It includes a heavy chain variable region and a light chain variable region; the light chain variable region includes L-CDR1, L-CDR2 and L-CDR3, and the heavy chain variable region includes H-CDR1, H-CDR2 and H-CDR3; The L-CDR1, L-CDR2 and L-CDR3 are respectively the following sequences: QSVSSNL, GAS, QQYHSWPPLT; The H-CDR1, H-CDR2 and H-CDR3 are respectively the following sequences: GYSFTSYG, ISAYNGNT, ARDFQGIAVADLDY.
2. The antibody or its antigen-binding fragment as described in claim 1, characterized in that, The amino acid sequence of the light chain variable region is shown in SEQ ID NO.1; the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.
3.
3. The antibody or its antigen-binding fragment as described in claim 1 or 2, characterized in that: The antibody or its antigen-binding fragment is selected from ScFv, Fab, and Fab'.
4. The antibody or its antigen-binding fragment as described in claim 3, characterized in that: The antibody or its antigen-binding fragment is ScFv.
5. The antibody or its antigen-binding fragment as described in claim 4, characterized in that: The ScFv is arranged in the form of VL-Linker-VH or VH-Linker-VL.
6. The antibody or its antigen-binding fragment as described in claim 5, characterized in that: The amino acid sequence of the Linker is shown in SEQ ID NO.
5.
7. A nucleic acid molecule, characterized by: It comprises encoding the antibody or antigen-binding fragment thereof as described in any one of claims 1-6.
8. The nucleic acid molecule as described in claim 7, characterized in that, The nucleotide sequence encoding the variable region of the antibody light chain is shown in SEQ ID NO.6; the nucleotide sequence encoding the variable region of the antibody heavy chain is shown in SEQ ID NO.
7.
9. A recombinant plasmid, characterized in that, It includes the nucleic acid molecule as described in any one of claims 7-8.
10. A chimeric antigen receptor, characterized in that, It comprises the antibody or antigen-binding fragment thereof as described in any one of claims 4-6.
11. The chimeric antigen receptor as described in claim 10, characterized in that: The chimeric antigen receptor includes ScFv as shown in SEQ ID NO. 8.
Citation Information
Patent Citations
Mutant fully-humanized antibody specifically binding to CD22 and application of mutant fully-humanized antibody
CN117924484A
